SYSTEMATIC REVIEW

Factor Xa inhibitor for venous thromboembolism management in patient with cancer: a systematic review and meta-analysis [version 1; peer review: awaiting peer review]

Johanes Nugroho Eko Putranto[1,2], Ardyan Wardhana[3], Yoga Alfian Noor[1,2], Pirhot Lambok Marnala Yosua Siahaan[2,4], Makhyan Jibril Al Farabi[1,4]

[1]Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia
[2]Dr. Soetomo General Hospital, Surabaya, Indonesia
[3]Faculty of Medicine, Universitas Surabaya, Surabaya, Indonesia
[4]Department of Anesthesia and Reanimation, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

v1 **First published:** 08 Dec 2021, **10**:1257
https://doi.org/10.12688/f1000research.73883.1
Latest published: 08 Dec 2021, **10**:1257
https://doi.org/10.12688/f1000research.73883.1

Abstract

Background: An earlier systematic review reported no differences in the incidence of recurrent venous thromboembolism and major bleeding between factor Xa inhibitors and standard anticoagulation. The present meta-analysis aimed to assess the effectiveness of factor Xa inhibitors for the management of venous thromboembolism (VTE), specifically in patients with cancer, as there were more randomized clinical trials (RCTs) available.

Methods: The PubMed and Cochrane Library databases were systematically screened for all RCTs assessing factor Xa inhibitor efficacy for VTE management in cancer patients. Using RevMan 5.3, we performed a Mantel–Haenszel fixed-effects meta-analysis of the following outcomes: recurrent VTE, VTE events, and major bleeding rates.

Results: We identified 11 studies involving 7,965 patients. Factor Xa inhibitors were superior in preventing VTE recurrence, compared to low-molecular-weight heparin (LMWH) (OR 0.60; 95% CI 0.45–0.80; P < 0.01) and vitamin K antagonists (VKA) (OR 0.51; 95% CI 0.33–0.78; P < 0.01). As prophylaxis, factor Xa inhibitors had a similar rate of VTE compared to VKAs (OR 1.08 [95% CI 0.31–3.77]; P = 0.90) and a lower rate compared to placebo (OR 0.54 [95% CI 0.35–0.81]; P < 0.01). Major bleeding rates were higher with factor Xa inhibitors than with LMWHs (OR 1.34 [95% CI 0.83–2.18]; P = 0.23), but significantly lower than VKAs (OR 0.71 [95% CI 0.55–0.92]; P < 0.01).

Conclusions: Factor Xa inhibitors are effective for VTE management in patients with cancer; however, they are also associated with an increased bleeding risk compared to LMWH, but decreased when compared to VKA.

Open Peer Review

Reviewer Status *AWAITING PEER REVIEW*

Any reports and responses or comments on the article can be found at the end of the article.

Keywords
bleeding, cancer, factor Xa inhibitor, oral anticoagulant, venous thromboembolism.

Corresponding author: Johanes Nugroho Eko Putranto (j.nugroho.eko@fk.unair.ac.id)

Author roles: Nugroho Eko Putranto J: Conceptualization, Investigation, Resources, Supervision, Validation, Writing – Review & Editing; **Wardhana A**: Data Curation, Formal Analysis, Investigation, Methodology, Writing – Original Draft Preparation; **Noor YA**: Investigation, Methodology, Project Administration, Resources, Software, Supervision, Writing – Original Draft Preparation; **Lambok Marnala Yosua Siahaan P**: Formal Analysis, Funding Acquisition, Investigation, Resources, Validation; **Al Farabi MJ**: Data Curation, Investigation, Project Administration, Resources, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This work was supported by the Indonesian Endowment Fund for Education (LPDP) Republic of Indonesia
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

How to cite this article: Nugroho Eko Putranto J, Wardhana A, Noor YA *et al.* **Factor Xa inhibitor for venous thromboembolism management in patient with cancer: a systematic review and meta-analysis [version 1; peer review: awaiting peer review]** F1000Research 2021, **10**:1257 https://doi.org/10.12688/f1000research.73883.1

First published: 08 Dec 2021, **10**:1257 https://doi.org/10.12688/f1000research.73883.1

Introduction

Cancer patients are five times more likely to experience venous thromboembolism (VTE) than the general population.[1] Second only to cancer itself, VTE is the second most common cause of mortality in cancer patients.[2] According to previous clinical management recommendations, the typical VTE treatment in cancer patients involves the initial use of parenteral low-molecular-weight heparin (LMWH) followed by long-term use of oral vitamin K antagonists (VKA).[3] However, recent recommendations proposed factor Xa inhibitors as one of the options of the main initial treatment for VTE.[4]

Factor Xa inhibitors are preferred over LMWH and VKA because they conveniently do not require injections every day compared to LMWH, their more predictable effects, lack of monitoring or frequent repeat doses, and fewer drug interactions compared to VKA.[5] An earlier systematic review reported differences between factor Xa inhibitors and standard anticoagulation drugs in the incidence of recurrent VTE and major bleeding.[6] Based on this research, the present meta-analysis aims to evaluate the effectiveness of factor Xa inhibitors for the management of venous thromboembolism, particularly in patients with cancer.

Ethical considerations

Ethical approval for this research was obtained from the Dr. Soetomo General Hospital Surabaya Ethical Committee in Health Research (1964/KEPK/IV/2020).

Trial registry

UMIN Clinical Trial Registry (UMIN ID 000040346).

Methods

We adopted the Preferred Reporting Items for Reviews and Meta-Analyses guidelines for analysis reporting.[7] Any RCTs that studied VTE rates or major bleeding, as primary or secondary outcomes, in cancer patients who received an oral factor Xa inhibitor were included. Phase II trials, trials with an antiplatelet control group, and trials using an anticoagulant as VTE post-procedure prophylaxis were excluded.

We conducted a systematic search using the PubMed and Cochrane Library databases on April 24, 2020, after gaining approval from the Institutional Review Board. As for the title, abstract, and medical subject heading, we used search terms like “cancer,” “factor Xa inhibitor,” “oral anticoagulant,” “venous thromboembolism,” “apixaban,” “rivaroxaban,” “edoxaban,” “prophylaxis,” “bleeding,” “thromboembolism,” “thromboprophylaxis,” “randomized,” and “rct.”

We screened more studies by looking at the references in the included articles. Two investigators independently selected studies, with disagreements resolved through discussion and a third investigator's opinion. Thereafter, for each report, two investigators independently extracted the following information: authors, year of publication, trial name, cancer status, sample size, dose and duration of anticoagulation, duration of patient follow-up, and outcomes for the two treatment groups where available.

We determined four comparison groups: (1) factor Xa inhibitor versus LMWH as treatment for VTE; (2) factor Xa inhibitor versus VKA as treatment for VTE; (3) factor Xa inhibitor versus placebo as prophylaxis for VTE; (4) factor Xa inhibitor versus VKA as prophylaxis for VTE. The outcomes of our meta-analysis were recurrent VTE or new VTE event rates and incidence of major bleeding. VTE events were confirmed by leg vein ultrasound scanning, D-dimer testing, or both; alternatively, clinically overt pulmonary embolism was confirmed by imaging. Major bleeding was defined as in Schulman *et al.*[8]

The Cochrane Collaboration Risk of Bias Tool was used by two independent investigators to assess the methodological quality of included studies, and the GRADE approach was employed to grade each outcome.[9,10] Any disputes were settled through discussion with a third investigator. We calculated odds ratios (ORs) for all outcomes at the longest follow-up period and used Review Manager (RevMan v5.3 2014) to apply the Mantel−Haenszel fixed-effects method. We conducted a modified intention-to-treat analysis including patients who had received ≥ 1 medication dose. We planned to a conduct sensitivity analysis by removing studies likely to be biased. The I2 statistic was used to assess statistical heterogeneity between studies. If the heterogeneity was > 50%, we applied a random-effects model for analysis.[11]

Results

The search identified 202 citations in PubMed and 41 in the Cochrane Library, among which 43 were duplicates (Figure 1). We found 22 more studies of which we evaluated the full text. Four studies were post-procedure prophylaxis



Figure 1. PRISMA flow diagram.

trials, three lacked a control, two were phase II trials, and two were extensions of included trials, so 11 were omitted. As a result, we could include 11 studies in our analysis.[12–22]

Table 1 lists the characteristics of the included studies. There were four trials on apixaban, four on rivaroxaban, and three on edoxaban. The study size ranged from 300 to 1,170 patients. Five studies were subgroup analyses of patients with cancer from larger primary trials.[12–16] We pooled their data only from the subgroup of patients with cancer, not all study population. One study was a pooled analysis of the subgroup of patients with cancer in "sister" trials.[17] Four trials[13,18–20] compared factor Xa inhibitors with LMWH, and three[12,14,17] compared factor Xa inhibitors with VKA as a VTE treatment. Two trials[15,16] compared factor Xa inhibitors with placebo and two[21,22] compared factor Xa inhibitors with VKA as prophylaxis of VTE. We included one trial that investigated two doses of edoxaban for VTE prophylaxis, where the outcomes of both groups were combined and analyzed as one intervention group.[16]

The risk of bias across domains is presented in Figure 2. In most studies, the randomization process, adherence to the intervention, assessment, missing outcome results, and reporting were deemed adequate. In four trials, participants were blinded. The percentage of patients not followed up ranged from 0.2% to 5.6%. All trials reported the results from modified intention-to-treat analysis.

Table 1. The characteristics of the included trials.

Author	Blinding to subjects	Population	Randomized patients	Intervention	Dose	Control	Follow up period	Death	Lost to follow up
Prins et al., 2013; EINSTEIN-DVT and PE	No	Cancer patients with VTE (100% active cancer)	597	Rivaroxaban	15 mg bid for 3 wk followed by 20 mg qd	Heparin/VKA	3-12 months	30% vs 35%	N/A
Agnelli et al., 2015; AMPLIFY	Yes	Cancer patients with VTE (31.6% active cancer)	534	Apixaban	10 mg bid for 7 d followed by 5 mg bid	Heparin/VKA	6 months	N/A	N/A
Raskob et al., 2016; HOKUSAI-VTE	Yes	Cancer patients with VTE (48% active cancer)	771	Edoxaban	60 mg once daily	Heparin/VKA	3-12 months	N/A	N/A
Raskop et al., 2017; HOKUSAI-VTE	No	Cancer patients with VTE (97.9% active cancer)	1050	Edoxaban	60 mg once daily	Dalteparin (200 UI/kg/d during 30 days, then 150 UI/kg/d)	12 months	39% vs 36%	0.8% (3 vs 5)
Young et al., 2017; SELECT-D	No	Cancer patients with VTE (100% active cancer)	406	Rivaroxaban	15 mg bid for 3 wk followed by 20 mg qd	Dalteparin (200 UI/kg/d during 30 days, then 150 UI/kg/d)	6 months	75% vs 70%	0.2% (0 vs 1)
McBane et al., 2018; ADAM VTE	No	Cancer patients with VTE (100% active cancer)	300	Apixaban	10 mg bid for 7 d followed by 5 mg bid	Dalteparin (200 UI/kg/d during 30 days, then 150 UI/kg/d)	6 months	15% vs 10%	5.6% (9 vs 7)
Fanola et al., 2018; ENGAGE AF-TIMI	No	Cancer patients with AF (100% active cancer)	1153	Edoxaban	60 mg once daily or 30 mg once daily	VKA	> 2 years	32% vs 30%	N/A
Chen et al., 2019; ROCKET AF	No	Cancer patients with AF (7.8% active cancer)	640	Rivaroxaban	20 mg qd	VKA	2 years	10% vs 15%	N/A
Carrier et al., 2019; AVERT	Yes	Ambulatory patients with risk of VTE	574	Apixaban	2.5 mg bid	Placebo	6 months	12% vs 10%	4.3% (13 vs 11)
Khorana et al., 2019; CASSINI	Yes	Ambulatory patients with risk of VTE	841	Rivaroxaban	10 mg qd	Placebo	6 months	20% vs 25%	N/A
Agnelli et al., 2020; CARAVAGGIO	No	Cancer patients with VTE (97.3% active cancer)	1170	Apixaban	10 mg bid for 7 d followed by 5 mg bid	Dalteparin (200 UI/kg/d during 30 days, then 150 UI/kg/d)	6 months	23% vs 25%	1.7% (12 vs 8)

F1000Research 2021, 10:1257 Last updated: 08 DEC 2021



Figure 2. Risk of bias assessment.

The quality of evidence for each outcome analyzed using the GRADE approach is presented in Table 2. We did not downgrade from the risk of bias, inconsistency, indirectness, and imprecision aspect of all outcomes, because of a low risk of bias, no substantial heterogeneity, a large enough sample size, and narrow confidence interval (CI). We downgraded one level for the major bleeding outcome because the funnel plot of major bleeding outcome suggested publication bias (Figure 3).

Seven studies involving 4,771 patients reported VTE recurrence (Table 2). Recurrence occurred in 4.9% (117/2,399) of patients allocated to factor Xa inhibitors, 9.1% (132/1,445) allocated to LMWHs, and 6.9% (64/927) of those allocated to VKAs. In comparison (Figure 4), the reduction of the risk of VTE recurrence with factor Xa inhibitors compared to LMWH was acceptable (four trials; OR 0.60; 95% CI 0.45–0.80; $P < 0.01$), without substantial heterogeneity ($I2 = 26\%$; $P = 0.26$). VTE recurrence rates were lower in patients treated with factor Xa inhibitors compared to patients treated using VKAs (three trials; OR 0.51; 95% CI 0.33–0.78; $P < 0.01$), without substantial heterogeneity ($I2 = 0\%$; $P = 0.37$).

Three studies, including 2,056 patients, reported the incidence of new VTE after anticoagulant prophylaxis. The factor Xa inhibitor group had a 4.1% (42/1,021) VTE occurrence rate, while the VKA and placebo groups each had 1.45% (5/355) and 9.6% (65/680), respectively. According to the meta-analysis shown in Figure 5, there were similar VTE incidences in the factor Xa inhibitor and the VKA groups (one trial; OR = 1.08 [95% CI, 0.31–3.77]; $P = 0.90$); however, the heterogeneity analysis could not be applied. The estimated effect of factor Xa inhibitors on VTE incidence compared to placebo showed a statistically significant reduction (two trials; OR = 0.54 [95% CI, 0.35–0.81]; $P < 0.01$), without substantial heterogeneity ($I2 = 31\%$; $P = 0.23$).

Table 2. Summary of findings.

	No of studies	Total participants	Pooled OR (95% CI)	P	I2 (P)	GRADE
Recurrence						High
vs LMWH	4	2890	0.60 (0.45, 0.80)	0.0004	26% (0.26)	
vs VKA	3	1881	0.51 (0.33, 0.78)	0.002	0% (0.37)	
New VTE						High
vs VKA	1	684	1.08 (0.31, 3.77)	0.90	N/A	
vs Placebo	2	1372	0.54 (0.35, 0.81)	0.003	31% (0.23)	
Major bleeding						Moderate
vs LMWH	4	2890	1.34 (0.83, 2.18)	0.23	28% (0.25)	
vs VKA	5	3703	0.71 (0.55, 0.92)	0.009	0% (0.72)	
vs Placebo	2	1372	1.98 (0.88, 4.44)	0.10	0% (0.96)	



Figure 3. Funnel plot of (A) recurrent VTE outcome; (B) new VTE outcome; (C) major bleeding outcome.



Figure 4. Forest plot of recurrent VTE outcome.

Eleven studies, including 7,965 patients, reported major bleeding (Table 2). Major bleeding occurred in 5.5% (231/4,178) of patients allocated to factor Xa inhibitors, 3.6% (52/1445) to LMWHs, 8.1% (134/1,662) to VKAs and 1.3% (9/680) to placebo. According to the meta-analysis shown in Figure 6, the acceptable increase of risk cannot be confirmed from the description of major bleeding with factor Xa inhibitors compared to LMWH, as based on an OR of 1.34 (95% CI, 0.83–2.18) with a P = 0.23, which is not statistically significant. However, factor Xa inhibitors significantly reduced the risk of major bleeding compared to VKAs (five trials; OR = 0.71 [95% CI, 0.55–0.92]; P = 0.009), without substantial heterogeneity (I2 = 0%; P = 0.72). The risk of major bleeding was higher with factor Xa inhibitors versus placebo



Figure 5. Forest plot of new VTE outcome.



Figure 6. Forest plot of major bleeding outcome.

(two trials; OR = 1.98 [95% CI, 0.88–4.44]; P = 0.10) but not statistically significant, without substantial heterogeneity (I2 = 0%; P = 0.96).

Discussion

The aim of this meta-analysis was to determine the efficacy and safety of factor Xa inhibitors for VTE treatment in cancer patients. Recurrence was 4.9%, 9.1%, and 6.9 % for the factor Xa inhibitor, LMWH, and VKA groups, respectively. All were lower than the findings of a retrospective cohort study which reported an incidence of 13.1%, 17.6%, and 17.9%, respectively.[23] Our review of four studies involving over 4,771 patients found that factor Xa inhibitors were associated with a lower risk of VTE recurrence when compared to LMWH, and even lower when compared to VKA. This result was consistent with a recent meta-analysis which combined data from RCTs and retrospective cohort studies.[24]

Another finding in our meta-analysis in terms of safety profiles was that factor Xa inhibitors were associated with an increased risk of bleeding when compared to LMWH, but a lower risk when compared to VKA. This result is in line with the findings of other systematic reviews.[24–26] However, another meta-analysis found a significantly higher incidence of bleeding (two trials, OR= 2.72 [95% CI: 1.05–7.01]; P= 0.039) with factor Xa inhibitors, relative to LMWH.[27] Importantly, the bleeding outcome in comparison to LMWH was the result of pooled data from nonspecific cancer patients. The results of the analysis of major bleeding in comparison to LMWH were mainly influenced by those of the HOKUSAI VTE Cancer trial and the recent CARAVAGGIO trial.[28,29] Both had different results: the former showed significantly higher bleeding in the edoxaban group while the second showed similar major bleeding events between groups.

Our meta-analysis also provided information about the efficacy of factor Xa inhibitors as prophylaxis, which suggested that, compared to placebo, it can significantly reduce VTE incidence. According to a recent clinical practice guideline, high-risk cancer outpatients can receive thromboprophylaxis with a factor Xa inhibitor or LMWH, in the absence of major risk factors for bleeding.[30] The high cost and the pain of daily LMWH injections was avoided with the factor Xa inhibitor regimen.

With respect to factor Xa inhibitors and LMWH, the inclusion of the CARAVAGGIO trial, with highly rigorous evidence, increased the accuracy of the estimated outcomes. There are a number of limitations to the current meta-analysis: the majority of the data corresponded to subgroup or post-hoc analyses. Further, the following variables were not controlled for: cancer stage, type of cancer, follow-up period. While most of the included studies evaluated patients for six months, the optimal duration of anticoagulation treatment was not evaluated to achieve an agreement. Finally, despite our systematic electronic database search and our investigation of the references in the included studies, we may have missed relevant studies.

Conclusion

Factor Xa inhibitors are effective for VTE management in patients with cancer; however, they are also associated with an increased bleeding risk compared to LMWH, but decreased when compared to VKA.

Data availability statement

Underlying data

All data underlying the results are available as part of the article and no additional source data are required.

Reporting guidelines[8]

Figshare: PRISMA checklist for 'Factor Xa inhibitor for venous thromboembolism management in Patients with cancer: a systematic review and meta-analysis'. https://doi.org/10.6084/m9.figshare.16590086.v3[31]

Acknowledgments

This work was performed as part of Johanes Nugroho employment at the Department of Cardiology and Vascular Medicine, Universitas Airlangga/Dr. Soetomo General Hospital, East Java, Indonesia. The authors also would like to thank Enago (www.enago.com) for the English language review and this work was supported by the Indonesian Endowment Fund for Education (Lembaga Pengelola Dana Pendidikan).

References

1. Elyamany G, Alzahrani AM, Bukhary E: **Cancer-associated thrombosis: an overview.** *Clin Med Insights Oncol.* 2014; **8**: 129–137.
PubMed Abstract | Publisher Full Text

2. Khorana AA, Francis CW, Culakova E, *et al.*: **Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy.** *J. Thromb. Haemost.* 2007; **5**: 632–634.
PubMed Abstract | Publisher Full Text

3. Kearon C, Akl EA, Comerota AJ, *et al.*: **Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.** *Chest.* 2012; **141**: e419S–e496S.
Publisher Full Text

4. Lyman GH, Carrier M, Ay C, *et al.*: **American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer.** *Blood Adv.* 2021; **5**(4): 927–974.
PubMed Abstract | Publisher Full Text

5. Fox BD, Kahn SR, Langleben D, *et al.*: **Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials.** *BMJ.* 2012; **345**: e7498.
PubMed Abstract | Publisher Full Text

6. Robertson L, Kesteven P, McCaslin JE: **Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism.** *Cochrane Database Syst. Rev.* 2015;

2016(Issue 12): Art. No.: CD010957.
Publisher Full Text

7. Moher D, Liberati A, Tetzlaff J, *et al.*: **The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement.** *Open Med.* 2009; **3**: 123–130.

8. Schulman S, Kearon C: **Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.** *J. Thromb. Haemost.* 2005; **3**: 692–694.
PubMed Abstract | Publisher Full Text

9. Sterne JAC, Savović J, Page MJ, *et al.*: **RoB 2: a revised tool for assessing risk of bias in randomised trials.** *BMJ.* 2019 Aug 28; **366**: l4898.
Publisher Full Text

10. Ryan R, Hill S: *How to GRADE the quality of the evidence Version 3.0.* Cochrane Consumers and Communication Group; 2018 Dec [cited 2019 July 13]; [about 25 p.].
Reference Source

11. Higgins JPT, Green S: *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0.* The Cochrane Collaboration; 2011 [cited 2019 July 10].
Reference Source

12. Raskob GE, van Es N, Segers A, *et al.*: **Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial.** *Lancet Haematol.* 2016; **3**: e379–e387.
PubMed Abstract | Publisher Full Text

13. Raskob GE, van Es N, Verhamme P, *et al.*: **on behalf of the Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism.** *N. Engl. J. Med.* 2018; **378**(7): 615–624.
Publisher Full Text

14. Agnelli G, Buller HR, Cohen A, *et al.*: **Oral apixaban for the treatment of venous thromboembolism in cancer patients: Results from the AMPLIFY trial.** *J. Thromb. Haemost.* 2015; **13**(12): 2187–2191.
PubMed Abstract | Publisher Full Text

15. Chen ST, Hellkamp AS, Becker RC, *et al.*: **Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF.** *Eur Heart J Qual Care Clin Outcomes.* 2019; **5**(2): 145–152.
PubMed Abstract | Publisher Full Text

16. Fanola CL, Ruff CT, Murphy SA, *et al.*: **Efficacy and safety of edoxaban in patients with active malignancy and atrial fibrillation: analysis of the ENGAGE AF - TIMI 48 trial.** *J Am Heart Assoc.* 2018; **7**(16): e008987.
PubMed Abstract | Publisher Full Text

17. Prins MH, Lensing AW, Bauersachs R, *et al.*: **Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies.** *Thromb J.* 2013; **11**(1): 21.
PubMed Abstract | Publisher Full Text

18. Agnelli G, Becattini C, Meyer G, *et al.*: **Apixaban for the treatment of venous thromboembolism associated with cancer.** *N Engl J Med.* 2020; **382**: 1599–1607.
Publisher Full Text

19. Young AM, Marshall A, Thirlwall J, *et al.*: **Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: Results of a randomized trial (SELECT-D).** *J Clin Oncol.* 2018; **36**(20): 2017–2023.
PubMed Abstract | Publisher Full Text

20. McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, *et al.*: **Apixaban, dalteparin, in active cancer associated venous thromboembolism, the ADAM VTE trial.** *Blood.* 2020; **18**(2): 411–421.

21. Khorana AA, Soff GA, Kakkar AK, *et al.*: **Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer.** *N Engl J Med.* 2019; **380**: 720–728.
PubMed Abstract | Publisher Full Text

22. Carrier M, Abou-Nassar K, Mallick R, *et al.* **Apixaban to prevent venous thromboembolism in patients with cancer.** *N Engl J Med.* 2019; **380**: 711–19.
Publisher Full Text | PubMed Abstract

23. Streiff MB, Mccrae K, Yannicelli D, *et al.*: **Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer.** *Am J Hematol.* 2018; **93**(5): 664–671.
PubMed Abstract | Publisher Full Text

24. Yang M, Li J, Sun R, *et al.*: **Comparison between direct factor Xa inhibitors and low-molecular-weight heparin for efficacy and safety in the treatment of cancer-associated venous thromboembolism: A meta-analysis.** *J Can Res Ther.* 2019; **15**: 1541–1546.
PubMed Abstract | Publisher Full Text

25. Fuentes HE, McBane RD 2nd, Wysokinski WE, *et al.*: **Direct Oral Factor Xa Inhibitors for the Treatment of Acute Cancer-Associated Venous Thromboembolism: A Systematic Review and Network Meta-analysis.** *Mayo Clin Proc.* 2019; **94**(12): 2444–2454.
PubMed Abstract | Publisher Full Text

26. Li A, Garcia DA, Lyman GH, *et al.*: **Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis.** *Thromb Res.* 2019; **173**: 158–163.
PubMed Abstract | Publisher Full Text

27. Brunetti ND, Gesuete E, De Gennaro L, *et al.*: **Direct oral anti-coagulants compared with vitamin-K inhibitors and low-molecular-weight-heparin for the prevention of venous thromboembolism in patients with cancer: A meta-analysis study.** *Int J Cardiol.* 2017; **230**: 214–221.
PubMed Abstract | Publisher Full Text

28. Hokusai VTE Cancer Investigators: **Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.** *N Engl J Med.* 2018; **378**: 673–674.
Publisher Full Text

29. Caravaggio Investigators: **Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.** *N Engl J Med.* 2020; **382**: 1599–1607.
Publisher Full Text

30. Key NS, Khorana AA, Kuderer NM, *et al.*: **Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update.** *J Clin Oncol.* 2020; **38**: 496–520.
PubMed Abstract | Publisher Full Text

31. Al Farabi, Jibril M: **PRISMA XA Checklist and Diagram. figshare.** *Dataset.* 2021.
Publisher Full Text


F1000Research
Search
SUBMIT YOUR RESEARCH
BROWSE
GATEWAYS & COLLECTIONS
HOW TO PUBLISH
ABOUT
BLOG
MY RESEARCH
SIGN IN
Publish fast. Openly. Without restrictions.
F1000Research is an Open Research publishing platform for scientists, scholars and clinicians offering rapid publication of articles and other research outputs without editorial bias.
HOW IT WORKS
SUBJECT AREAS | Browse all →
Natural Sciences
Medical and Health Sciences
Social Sciences
Engineering and Technology
Agricultural and Veterinary Sciences
Humanities and the Arts
RECENT ARTICLES | Browse all →
20 APRIL 2022
Determinants of patient behavioural loyalty on primary health centres: Evidence from ...
19 APRIL 2022
Comparison of clinical effectiveness of conventional and self-etch sealant: a split...
19 APRIL 2022
Adverse drug reactions to the three doses of the severe acute respiratory syndrome ...

Medical and Health Sciences

Medicine and health sciences focuses on the provision of healthcare, the prevention and treatment of human diseases and interventions and technology for use in healthcare to improve the treatment of patients.

Advisory Board

The Advisory Board of F1000Research comprises a large group of leading experts across biology and medicine. They do not act as Editors in the traditional sense (they do not handle manuscripts or make decisions to accept or reject a paper), but they provide strategic input on the direction we should take with F1000Research. They occasionally advise us on issues arising with specific articles, and many members of the board also review for us.

A B C D E F G H I J K L M N O P R S T U V W X Y Z

B

Ian Beales
Nelson Bennett
Avri Ben-Ze'ev
Benedikt Berninger
Eric Beyer
Azra Bihorac
Daniel Bikle
Kevin J Black
Chellakkan Selvanesan Blesson
Erin Aiello Bowles
Bruce Brew

C

David Catcheside
Andrew Chalmers
Tak Mao Chan
Karen Chapman
Declan Chard
Walter Chazin
Jonathan Chernoff
Cheng-Ming Chiang
Ryan Chisholm
Wei-Sheng Chong
Sandra Citi
Vitaly Citovsky
Tim Clark
James Coker
Giuseppe Colloca
William Colmers
Jason Crawford
David Criddle

D

Ira Daar
Linda Dagi
Blossom Damania
Eric Dannaoui
Vinicio de Jesus Perez
Sharon DeMorrow
Gonzalo G de Polavieja
Saskia de Wildt
Harriet de Wit
Eleftherios P Diamandis
Phedias Diamandis
Betty Diamond
J Alan Diehl
Petya Dimitrova
Annette Dolphin
Lucy Donaldson
Sylvie Doublié
Paschalis-Thoma Doulias
Crislyn D'Souza-Schorey
James Duffin
Janice Du Mont

E

Sharyn Endow
Markus Engstler
Sam Enna
Erim Erdem

F

Alastair Ferguson
Gerardo Ferrara
Richard Festenstein
Thomas Finger
Céline Fiset
Heike Fölsch
Steven Frank
Bernd Fritzsch

G

Gus Gazzard
Jozef Gécz
Robert Gerlai
Ivan Gerling
Carole Goble
Richard Gomer
Andrew Goryachev
John Greenspan
Guy Griebel
W Sue Griffin
Elizabeth Grove
Jaime Grutzendler

Wei Guo

H

Adam Hartman
Johannes Hell
Winston Hide
Stephen Hoffman
Stephen Holgate
Thorsten Hoppe
Wolfgang Huber
Arthur Hurwitz

I

Radu Iliescu
Robert Insall
Harry Ischiropoulos

J

Jan Jakobsson
Guilhem Janbon
Michael Joannidis
Norman Johnson
Etienne Joly

K

Dieter Kabelitz
Wael Kafienah
Chaya Kalcheim
Lynn Kamerlin
Mikhail Kazachkov
Johannes S Kern
Jean-Pierre Kinet
Edward Kipreos
Fenella Kirkham
Gordon Klein
Alisa Koch
Amos Korczyn
Benoit Kornmann
Jan Kucera
Anuj Kumar
Saravana Kumar

L

Eileen Lafer
Hans Lassmann
Mario Lebendiker
John Lee
Laurel Lenz
Simon Levin
Stefan Linder
Ton Lisman
Creighton M Litton
Hartmut Lode

Theresa Lu
Robyn Lucas
Ben Lugtenberg
Paul Lyons

M

Roberto Maggi
Martin Marinus
M Rashad Massoud
Jocelyn McDonald
Robert McPeek
Anthony Means
Julien Mendlewicz
Arthur Mercurio
Ralph Mistlberger
Ali Mobasheri
David Moher
Randall Moon
Carlos Morel
Dimitrios Morikis
Nicola Mulder

N

Corey Nislow

O

Chiadi Onyike

P

Leonid Padyukov
Eleftherios Paschalis
Graham Pawelec
Ming Pei
Giampaolo Perna
Stephen Pinfield
Michel Pohl
Simon Portsmouth
David Potter
Chaim Putterman

R

Adam Ratner
Ana Recober
Victor Reus
José Luis Riechmann
Karin Romisch
Vincent Rotello
Barry Rouse
Gloria Rudenko
James Russell

S

Philippe Saas
Paul R Sanberg

Alan Schechter
Werner Scheithauer
Tamar Schlick
Thomas Schnider
Alfons Schnitzler
Irene Schulz
Michael Sendtner
Andrew D Sharrocks
Nilabh Shastri
Kazim Sheikh
Andrew Shennan
Xiao Shifu
Chiara Simonelli
Helmy Siragy
Cassian Sitaru
Richard Smith
H Peter Soyer
Pamela Stanley
Christoph Stein
Carly Stevens
Charles Stevens
Bruno Stieger

T

Paul-Peter Tak
Paul Terry
Igor Tetko
Jacques Thibodeau
Jakub Tolar
Peter Tonellato
Francis Tsai
Takeshi Tsubata
Tom Tullius
Burkhard Tümmler

U

Hisashi Umemori
Shiro Urayama
Vladimir Uversky

V

Hans van Beek
Hans van Bokhoven
Martin van den Berg
Peter Van Endert
Dirk van Helden
Chandra Verma
Jan Vermorken
David Voehringer

W

Claire Walczak

Nick Ward
Peter Wark
Stephen Waxman
Alan Wein
Tom Woodcock
Long-Jun Wu
Jeremy C Wyatt
Kevan Wylie

X

Yongbiao Xue

Y

Michael B Yaffe
Kenneth Yamada
Helen Yap
Dorothy Yuan

Z

Yunde Zhao
Deyou Zheng
Guy Zimmerman
Christos Zouboulis

RESEARCH ARTICLE metrics *AWAITING PEER REVIEW*

Quantitative image analysis in COVID-19 acute respiratory distress syndrome: a cohort observational study. [version 1; peer review: awaiting peer review]

Tamas Dolinay, Dale Jun, Abigail Maller, Augustine Chung, Brandon Grimes, Lillian Hsu, David Nelson, Bianca Villagas, Grace Hyun J Kim, Jonathan Goldin

PEER REVIEWERS *Invited*

PUBLISHED 09 Dec 2021

RESEARCH ARTICLE metrics

REVISED **Comparison of sleep and health behaviors among diabetic patients and non-diabetics in Phitsanulok, Thailand: a cross-sectional study [version 2; peer review: 1 approved, 1 approved with reservations]**

Chudchawal Juntarawijit, Yuwayong Juntarawijit

PEER REVIEWERS *Anastasia Thanopoulou; Ahmad Alkhatib*

FUNDER Naresuan University

LATEST VERSION PUBLISHED 09 Dec 2021

SYSTEMATIC REVIEW metrics

Factor Xa inhibitor for venous thromboembolism management in patient with cancer: a systematic review and meta-analysis [version 1; peer review: 2 approved]

Johanes Nugroho Eko Putranto, Ardyan Wardhana, Yoga Alfian Noor, Pirhot Lambok Marnala Yosua Siahaan, Makhyan Jibril Al Farabi

PEER REVIEWERS *Suko Adiarto; Irene Terrenato*

FUNDER Indonesian Endowment Fund for Education (LPDP-Lembaga Pengelola Dana Pendidikan RI)

PUBLISHED 08 Dec 2021

RESEARCH ARTICLE metrics

REVISED ## Enhancement of pyocyanin production by subinhibitory concentration of royal jelly in *Pseudomonas aeruginosa* [version 4; peer review: 3 approved, 1 approved with reservations]

Dina Auliya Amly, Puspita Hajardhini, Alma Linggar Jonarta, Heribertus Dedy Kusuma Yulianto, Heni Susilowati

PEER REVIEWERS *Ariadna A. Djais; Theerthankar Das; Shizuo Kayama; Philip S. Bird*

FUNDER Ministry of Research, Technology and Higher Education, Republic of Indonesia

LATEST VERSION PUBLISHED 07 Dec 2021

RESEARCH ARTICLE metrics

REVISED ## Current situation of vaccine injury compensation program and a future perspective in light of COVID-19 and emerging viral diseases [version 2; peer review: 2 approved]

Tommie Crum, Kirsten Mooney, Birendra R. Tiwari

PEER REVIEWERS *Lal Rawal; Keshab Parajuli*

LATEST VERSION PUBLISHED 07 Dec 2021

RESEARCH ARTICLE metrics

Globalization and life lost due to tuberculosis: evidence from a multi-country study [version 1; peer review: 2 approved, 1 approved with reservations]

Shyamkumar Sriram, Muayad Albadrani

PEER REVIEWERS *Setya Haksama; Mohamed Adil AA; Arutselvi Devarajan*

PUBLISHED 07 Dec 2021

RESEARCH ARTICLE metrics

REVISED Local attributable burden disease to $PM_{2.5}$ ambient air pollution in Medellín, Colombia, 2010–2016 [version 2; peer review: 2 approved]

Hugo Grisales-Romero, Juan Gabriel Piñeros-Jiménez, Emmanuel Nieto, Sandra Porras-Cataño, Nora Montealegre, Difariney González, Dorian Ospina

PEER REVIEWERS *Pablo Enrique Chaparro Narváez; Carmen Ildes Rodrígues Fróes Asmus*

FUNDER This study was funded by the Science, Technology and Innovation program, Colciencias, through call 744-2016, contract No. 633-2017

LATEST VERSION PUBLISHED 06 Dec 2021

STUDY PROTOCOL metrics

REVISED Influence of surface peripheral electrical stimulation on nerve regeneration after digital nerve neurorrhaphy: study protocol for a

randomized clinical trial [version 2; peer review: 2 approved]

Enilton Mattos, Alex Guedes, Paulo Itamar Ferraz Lessa, Abrahão Fontes Baptista

PEER REVIEWERS *Yumin Yang; Jonas Kolbenschlag and Johannes Heinzel*

LATEST VERSION PUBLISHED 06 Dec 2021

RESEARCH ARTICLE metrics

REVISED **Flow cytometry of bone marrow aspirates from neuroblastoma patients is a highly sensitive technique for quantification of low-level neuroblastoma [version 2; peer review: 2 approved]**

Neha Jain, Shaista Sattar, Sarah Inglott, Susan Burchill, Jonathan Fisher, Andreea-Madalina Serban, Rebecca Thomas, Chris Connor, Niharendu Ghara, Tanzina Chowdhury, Catriona Duncan, Giuseppe Barone, John Anderson

PEER REVIEWERS *Godelieve A. M. Tytgat; Toby Trahair*

LATEST VERSION PUBLISHED 06 Dec 2021

OPINION ARTICLE metrics

COVID-19, pseudo-declining skin cancer rates and the rise of teledermatology [version 1; peer review: 1 approved]

Joanna Ludzik, Claudia Lee, Alexander Witkowski

PEER REVIEWER *Alessandro Laghi*

PUBLISHED 03 Dec 2021

SOFTWARE TOOL ARTICLE metrics *AWAITING PEER REVIEW*

NaijaCovidAPI: an application programming interface for retrieval of COVID19 data from the

Interface for retrieval of COVID19 data from the Nigerian Center for Disease Control web platform [version 1; peer review: awaiting peer review]

Emmanuel Baldwin Mbaya, Babatunde Alao, Philip Ewejobi, Innocent Nwokolo, Victoria Oguntosin, Emmanuel Adetiba

PEER REVIEWERS *Invited*

PUBLISHED 02 Dec 2021

CASE REPORT metrics

REVISED

Case Report: A Case of Encephalopathy Presenting the Lentiform Fork Sign on MRI in a Diabetic Dialysis Patient [version 3; peer review: 2 approved]

Yuri Ishizaki, Ryuzoh Nishizono, Masao Kikuchi, Hiroko Inagaki, Yuji Sato, Shouichi Fujimoto

PEER REVIEWERS *Shashwati Sarkar Sen; Ping-Hsun Wu*

LATEST VERSION PUBLISHED 02 Dec 2021

METHOD ARTICLE metrics *AWAITING PEER REVIEW*

Improved retinal vessel segmentation using the enhanced pre-processing method for high resolution fundus images [version 1; peer review: awaiting peer review]

Aziah Ali, Aini Hussain, Wan Mimi Diyana Wan Zaki, Wan Haslina Wan Abdul Halim, Wan Noorshahida Mohd Isa, Noramiza Hashim

PEER REVIEWERS *Invited*

FUNDER Ministry of Higher Education, Malaysia

PUBLISHED 01 Dec 2021

RESEARCH ARTICLE metrics

Priorities for research in child and adolescent anxiety and depression: a priority setting partnership with youth and professionals [version 1; peer review: 2 not approved]

Brynhildur Axelsdóttir, Lise Mette Eidet, Ragnhild Thoner, Sølvi Biedilæ, Ingrid Borren, Mari Elvsåshagen, Kristine Horseng Ludvigsen, Astrid Dahlgren

PEER REVIEWERS *Kristina Staley; Judith Borghouts*

PUBLISHED 01 Dec 2021

CASE REPORT metrics *AWAITING PEER REVIEW*

Case Report: Poor oral hygiene leading to an emergency condition: A case report of Ludwig's angina [version 1; peer review: awaiting peer review]

Prashant Pant, Oshan Shrestha, Pawan Budhathoki, Nebula Devkota, Prabin Kumar Giri, Dhan Bahadur Shrestha

PEER REVIEWERS *Invited*

PUBLISHED 01 Dec 2021

STUDY PROTOCOL metrics

REVISED The perspectives of patients and their caregivers on self-management interventions for chronic conditions: a protocol for a mixed-methods overview [version 2; peer review: 2 approved]

Ena Niño de Guzmán, Laura Martínez García, Ana I. González, Monique Heijmans, Jorge Huaringa, Kaisa Immonen, Lyudmil Ninov, Carola Orrego-Villagrán, Javier Pérez-Bracchiglione, Karla Salas-Gama, Andrés Viteri-García, Pablo Alonso-Coello

PEER REVIEWERS *Milena Vainieri; Edward Zimbudzi*

FUNDERS Instituto de Salud Carlos III | Horizon 2020

LATEST VERSION PUBLISHED 29 Nov 2021

RESEARCH ARTICLE metrics

REVISED **Long-term effect of full-body pulsed electromagnetic field and exercise protocol in the treatment of men with osteopenia or osteoporosis: A randomized placebo-controlled trial [version 3; peer review: 2 approved]**

Anwar Ebid, Mohamed El-boshy, Shamekh El-Shamy, Ali Thabet, Mohamed Abedalla, Tariq Ali

PEER REVIEWERS *Hesham Galal Mahran; Mohamed Taher Ahmed Omar*

FUNDER This work was funded by grant number 15-MED5406-10 from the National Science, Technology and Innovation Plan (MAARIFAH), the King Abdul-Aziz City for Science and Technology (KACST), Kingdom of Saudi Arabia

LATEST VERSION PUBLISHED 29 Nov 2021

RESEARCH ARTICLE metrics *AWAITING PEER REVIEW*

A systematic review of ePCR systems on reducing the response time of prehospital medical care [version 1; peer review: awaiting peer review]

ALI JASBI, Saravanan Muthaiyah, Thein Oak Kyaw Zaw

PEER REVIEWERS *Invited*

PUBLISHED 26 Nov 2021

CASE REPORT metrics

REVISED **Case Report: Portal cavernoma related to multiple liver hydatidosis: A rare case of fatal cataclysmic haemorrhage [version 2; peer review: 2 approved]**

review: 2 approved]

Alia Zouaghi, Nawel Bellil, Khalaf Ben Abdallah, Dhafer Hadded, Haithem Zaafouri, Mona Cherif, Anis Ben Maamer

PEER REVIEWERS *Souheil Zayet; Khaoula Chabbouh*

LATEST VERSION PUBLISHED 25 Nov 2021

RESEARCH ARTICLE metrics

REVISED Refining the content and design of an alcohol reduction app, *Drink Less*, to improve its usability and effectiveness: a mixed methods approach [version 2; peer review: 2 approved]

Claire Garnett, Olga Perski, Susan Michie, Robert West, Matt Field, Eileen Kaner, Marcus R. Munafò, Felix Greaves, Matthew Hickman, Robyn Burton, Jamie Brown

PEER REVIEWERS *Andre Bedendo; Maria Lucia O. Souza Formigoni*

FUNDERS Economic and Social Research Council | National Institute for Health Research School for Public Health Research | UK Centre for Tobacco and Alcohol Studies | British Heart Foundation | Cancer Research UK | National Institute for Health Research | Medical Research Council | Society for the Study of Addiction

LATEST VERSION PUBLISHED 25 Nov 2021

321-340 of 2,927 ARTICLES

See guidelines and policies.

F1000Research

An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.

BROWSE
GATEWAYS
COLLECTIONS
HOW IT WORKS

BLOG
CONTACT
RSS

Follow us